Blueprint Medicines rises after lifting AYVAKIT's FY revenue forecast

 ** Shares of Blueprint Medicines BPMC.O rise 7.98% to $90.06; opened at a two-month high before paring some gains

** Co lifts its gastrointestinal cancer medicine AYVAKIT's net product revenue forecast for FY24

** Co now expects about $475 mln to $480 mln in global AYVAKIT net product revenues in 2024, an increase from the previous range of $435 mln to $450 mln

** This updated outlook is based on continued growth in patients on therapy, continued favorability in compliance and other performance factors, and stronger-than-expected performance outside of the U.S. - Co

** BPMC reported a Q3 pretax profit of $56.003 mln, lower than estimates of $61 mln- LSEG

** Average rating on the stock is "buy" or higher; median PT is $128

** Including session's move, stock down ~3% YTD

https://www.xm.com/research/markets/allNews/reuters/blueprint-medicines-rises-after-lifting-ayvakits-fy-revenue-forecast-53956880